Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029
The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. Increasing need for cost and time reduction in the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive clinical trials. But there are some restraining factors in the market; the cost of biosimulation technologies is discouragingly high and thus, prohibitive to small companies and the academic community.
“Drug Discovery held the largest market share in the biosimulation market in 2023, by application.”
The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.
“By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period.”
By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.
“Asia Pacific is estimated to register the highest CAGR over the forecast period.”
The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.
Breakdown of supply-side primary interviews by company type, designation, and region:
This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“Drug Discovery held the largest market share in the biosimulation market in 2023, by application.”
The biosimulation market is segmented based on application into drug discovery, drug development, disease modelling, manufacturing & supply chain management and other applications. The drug discovery segment held the largest market share in 2023, since it plays a vital role in accelerating and enriching early stages of pharmaceutical research. The tool created by biosimulation makes it possible for the researchers to simulate drug behavior at the molecular level, predict biological target interaction, even identify potential drug candidates before they reach the costly phases of preclinical and clinical trial stages. It reduces both the time and the cost incurred during the process of drug development.
“By deployment model, the cloud-based model segment is expected to register the fastest growth over the forecast period.”
By deployment model, the biosimulation market is divided into on-premises, cloud-based and hybrid model. The cloud-based segment is projected to be the fastest-growing segment over the forecast period. Cloud-based platforms are much more flexible and scalable and make very significant computational resources available at the point when they are needed to run complex biosimulations. This flexibility makes cloud models highly cost-effective, particularly for smaller biotech firms and academic institutions that would lack the infrastructure for high-performance computing.
“Asia Pacific is estimated to register the highest CAGR over the forecast period.”
The biosimulation market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific biosimulation market is projected to register highest CAGR during the forecast period. The growth of this region is due to an aggressive build-out of the pharmaceutical and biotechnology industry in this region, especially in China, India, and South Korea, where large investments are committed to drug discovery and development. Markets in this region increasingly embrace sophisticated technology, such as biosimulation, to rationalize their R&D processes, reduce costs, and accelerate their time-to-market for new drugs.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
- By Designation: Managers (40%), Directors (35%), and Others (25%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)
- Certara USA. (US)
- Simulations Plus. (US)
- Dassault Syst?mes (France)
- Schrцdinger, Inc. (US)
- Advanced Chemistry Development, Inc. (Canada)
- Chemical Computing Group ULC. (Canada)
- Rosa & Co. LLC. (US)
- Genedata AG (US)
- Physiomics Plc (United Kingdom)
- In Silico Biosciences. (US)
- Allucent. (US)
- OpenEye, Cadence Molecular Sciences. (US)
- Cellworks Group, Inc. (US)
- VeriSIM Life. (US)
- Netabolics SRL (Italy)
- Charnwood Discovery (United Kingdom)
- The MathWorks, Inc. (US)
- ANSYS, Inc (US)
- Instem Group of Companies (United Kingdom)
- Insilico Medicine (US)
- SCM – Software Chemistry & Materials (Netherlands)
- BioSymetrics, Inc. (Canada)
- Atomwise Inc. (US)
- insitro. US)
- Clinithink. (US)
This research report categorizes the biosimulation market by offerings (software and services), application (drug discovery, drug development, disease modelling, manufacturing & supply chain and other applications), therapeutic area (oncology, cardiovascular disease, neurological disorders, infectious disease, and others), revenue model (license-based model, subscription-based model, service-based model, and pay-per-use model), deployment model (on-premises model, cloud-based model, and hybrid model) end user (pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutions, regulatory bodies and others), and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall biosimulation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers: (increase in R&D investments in the pharmaceutical and biotechnology industries), restraints (lack of standardization), opportunities (use of biosimulation solution for pediatric drug development), and challenges (difficulty in matching the complexity of biological systems and processes) influencing the growth of the biosimulation market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the biosimulation market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the biosimulation market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the biosimulation market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Certara USA. (US), Simulations Plus. (US), Dassault Syst?mes (France), Schrцdinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), etc. among others in biosimulation market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 BIOSIMULATION MARKET OVERVIEW
4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023)
4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024?2029)
4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP)
5.2.1.4 Need to curtail drug discovery and development costs
5.2.1.5 Growth in biologics and biosimilars markets
5.2.2 RESTRAINTS
5.2.2.1 Lack of standardization
5.2.2.2 Data availability and quality
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging applications
5.2.3.2 Use of biosimulation solutions for pediatric drug development
5.2.4 CHALLENGES
5.2.4.1 Difficulties in matching complexity of biological systems and processes
5.2.4.2 Shortage of biosimulation and modeling experts
5.3 ECOSYSTEM ANALYSIS
5.3.1 SOFTWARE PROVIDERS
5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES
5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
5.3.4 REGULATORY BODIES
5.3.5 ACADEMIC & RESEARCH INSTITUTIONS
5.4 CASE STUDY ANALYSIS
5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING
5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER
5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
5.5 VALUE CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
5.6.1 BARGAINING POWER OF SUPPLIERS
5.6.2 BARGAINING POWER OF BUYERS
5.6.3 THREAT OF SUBSTITUTES
5.6.4 THREAT OF NEW ENTRANTS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY ANALYSIS
5.7.1 REGULATORY LANDSCAPE
5.7.1.1 North America
5.7.1.2 Europe
5.7.1.3 Asia Pacific
5.7.1.4 Latin America
5.7.1.5 Middle East & Africa
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Mathematical modeling
5.9.1.2 Software platforms
5.9.1.3 Quantitative systems pharmacology (QSP)
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Data analytics
5.9.2.2 Machine learning and AI
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 In silico trials
5.10 INDUSTRY TRENDS
5.10.1 DISCOVERY OF BIOMARKERS
5.10.2 ADOPTION IN PERSONALIZED MEDICINE
5.11 PRICING ANALYSIS
5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE)
5.12 KEY CONFERENCES & EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 BUYING CRITERIA
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.15 END-USER ANALYSIS
5.15.1 UNMET NEEDS
5.15.2 END-USER EXPECTATIONS
5.16 INVESTMENT & FUNDING SCENARIO
5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET
5.17.1 KEY USE CASES
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.17.2.1 Case study
5.17.2.2 Bioinformatics market
5.17.2.3 Drug discovery services market
5.17.2.4 Drug discovery informatics market
5.17.3 USER READINESS & IMPACT ASSESSMENT
5.17.3.1 User readiness
5.17.3.1.1 Pharmaceutical & biotechnology companies
5.17.3.1.2 Contract research organizations
5.17.3.2 Impact assessment
5.17.3.2.1 User A: Pharmaceutical & biotechnology companies
5.17.3.2.1.1 Implementation
5.17.3.2.1.2 Impact
5.17.3.2.2 User B: Academic & research institutes
5.17.3.2.2.1 Implementation
5.17.3.2.2.2 Impact
6 BIOSIMULATION MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 SOFTWARE
6.2.1 STANDALONE MODULES
6.2.1.1 Molecular modeling & simulation software
6.2.1.1.1 Growing importance of molecular modeling & simulation in drug discovery and development to accelerate market growth
6.2.1.2 PK/PD modeling & simulation software
6.2.1.2.1 Pivotal role in early drug development phase to boost market growth
6.2.1.3 PBPK modeling & simulation software
6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market
6.2.1.4 Toxicity prediction software
6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market
6.2.1.5 Clinical trial simulation software
6.2.1.5.1 High failure rate of clinical trials to accelerate growth
6.2.1.6 Other biosimulation software
6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS
6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms
6.3 SERVICES
6.3.1 CONSULTING & ADVISORY
6.3.1.1 Need to focus on core competencies to drive need for consulting & advisory services
6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT
6.3.2.1 Need for well-trained professionals and experts to accelerate market growth
6.3.3 DATA ANALYSIS & INTERPRETATION
6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services
7 BIOSIMULATION MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DRUG DISCOVERY
7.2.1 TARGET IDENTIFICATION & VALIDATION
7.2.1.1 Need for identification of optimal targets in drug discovery to drive market
7.2.2 LEAD IDENTIFICATION & OPTIMIZATION
7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate market growth
7.3 DRUG DEVELOPMENT
7.3.1 PRECLINICAL TESTING
7.3.1.1 PK/PD
7.3.1.1.1 Critical role of PK/PD studies in drug development to drive market
7.3.1.2 ADME/Toxicology
7.3.1.2.1 Growing role in selection of potent drug molecules to boost market growth
7.3.2 CLINICAL TRIALS
7.3.2.1 Phase I
7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth
7.3.2.2 Phase II
7.3.2.2.1 Efficiency in dose assessment and product efficacy to drive growth
7.3.2.3 Phase III
7.3.2.3.1 Need to curtail large costs involved in trials to propel demand
7.3.2.4 Phase IV/Post-marketing surveillance
7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption
7.4 DISEASE MODELING
7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH
7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
7.5.1 PRODUCTION PLANNING & OPTIMIZATION
7.5.1.1 Need for proper production planning and execution to drive market growth
7.5.2 QUALITY CONTROL & PROCESS MONITORING
7.5.2.1 Adherence to maintaining product quality to fuel market growth
7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT
7.5.3.1 Need to forecast demand effectively to drive market growth
7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING
7.5.4.1 Need to maintain operational continuity to support market growth
7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS
7.6 OTHER APPLICATIONS
8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH
8.3 CARDIOVASCULAR DISEASES
8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET
8.4 NEUROLOGICAL DISORDERS
8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
8.5 INFECTIOUS DISEASES
8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
8.6 OTHER THERAPEUTIC AREAS
9 BIOSIMULATION MARKET, BY REVENUE MODEL
9.1 INTRODUCTION
9.2 LICENSE-BASED MODELS
9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET
9.3 SUBSCRIPTION-BASED MODELS
9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
9.4 SERVICE-BASED MODELS
9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION
9.5 PAY-PER-USE MODELS
9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH
10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL
10.1 INTRODUCTION
10.2 ON-PREMISE MODELS
10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
10.3 CLOUD-BASED MODELS
10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD
10.4 HYBRID MODELS
10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION
11 BIOSIMULATION MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
11.3 CONTRACT RESEARCH ORGANIZATIONS
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
11.4 ACADEMIC & RESEARCH INSTITUTES
11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
11.5 REGULATORY BODIES
11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH
11.6 OTHER END USERS
12 BIOSIMULATION MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Rising government funding for pharmaceutical R&D to drive market
12.2.3 CANADA
12.2.3.1 Increasing funding by Canadian government in healthcare to drive market
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation
12.3.3 UK
12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
12.3.4 FRANCE
12.3.4.1 Growing R&D pipeline for clinical trials to drive market
12.3.5 ITALY
12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
12.3.6 SPAIN
12.3.6.1 Established network of research centers to propel market
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market
12.4.3 INDIA
12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation
12.4.4 JAPAN
12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth
12.4.5 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Advancing biosimulation in region to support market growth
12.5.3 MEXICO
12.5.3.1 Government initiatives to enhance digital health to propel market growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12.6.2 GCC COUNTRIES
12.6.2.1 Increase in healthcare investments to support market growth
12.6.3 REST OF MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET
13.3 REVENUE ANALYSIS, 2019–2023
13.4 MARKET SHARE ANALYSIS, 2023
13.4.1 CERTARA, USA (US)
13.4.2 DASSAULT SYST?MES (FRANCE)
13.4.3 SCHRЦDINGER, INC. (US)
13.4.4 SIMULATIONS PLUS (US)
13.4.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. (CANADA)
13.5 RANKING OF KEY MARKET PLAYERS
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.6.1 STARS
13.6.2 EMERGING LEADERS
13.6.3 PERVASIVE PLAYERS
13.6.4 PARTICIPANTS
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.6.5.1 Company footprint
13.6.5.2 Offering footprint
13.6.5.3 Application footprint
13.6.5.4 End-user footprint
13.6.5.5 Region footprint
13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023
13.7.1 PROGRESSIVE COMPANIES
13.7.2 RESPONSIVE COMPANIES
13.7.3 DYNAMIC COMPANIES
13.7.4 STARTING BLOCKS
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.8 COMPANY EVALUATION & FINANCIAL METRICS
13.9 BRAND/PRODUCT COMPARISON
13.10 COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
13.10.2 DEALS
13.10.3 EXPANSIONS
13.10.4 OTHER DEVELOPMENTS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 CERTARA, USA
14.1.1.1 Business overview
14.1.1.2 Products & services offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches & enhancements
14.1.1.3.2 Deals
14.1.1.4 MnM view
14.1.1.4.1 Right to win
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 DASSAULT SYST?MES
14.1.2.1 Business overview
14.1.2.2 Products & services offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Right to win
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 SCHRЦDINGER, INC.
14.1.3.1 Business overview
14.1.3.2 Products & services offered
14.1.3.3 Recent developments
14.1.3.3.1 Deals
14.1.3.4 MnM view
14.1.3.4.1 Right to win
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 SIMULATIONS PLUS
14.1.4.1 Business overview
14.1.4.2 Products & services offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches & enhancements
14.1.4.3.2 Deals
14.1.4.3.3 Other developments
14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC.
14.1.5.1 Business overview
14.1.5.2 Products & services offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches & enhancements
14.1.5.3.2 Deals
14.1.6 CHEMICAL COMPUTING GROUP ULC
14.1.6.1 Business overview
14.1.6.2 Products & services offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 ROSA & CO. LLC
14.1.7.1 Business overview
14.1.7.2 Products & services offered
14.1.8 GENEDATA AG (A DANAHER COMPANY)
14.1.8.1 Business overview
14.1.8.2 Products & services offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches & enhancements
14.1.8.3.2 Deals
14.1.9 PHYSIOMICS PLC
14.1.9.1 Business overview
14.1.9.2 Products & services offered
14.1.9.3 Recent developments
14.1.9.3.1 Deals
14.1.10 IN SILICO BIOSCIENCES
14.1.10.1 Business overview
14.1.10.2 Products & services offered
14.1.11 ALLUCENT
14.1.11.1 Business overview
14.1.11.2 Products & services offered
14.1.11.3 Recent developments
14.1.11.3.1 Deals
14.1.11.3.2 Expansions
14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES
14.1.12.1 Business overview
14.1.12.2 Products & services offered
14.1.12.3 Recent developments
14.1.12.3.1 Product enhancements
14.1.12.3.2 Deals
14.1.12.3.3 Expansions
14.1.13 CELLWORKS GROUP, INC.
14.1.13.1 Business overview
14.1.13.2 Products & services offered
14.1.13.3 Recent developments
14.1.13.3.1 Expansions
14.1.14 VERISIM LIFE
14.1.14.1 Business overview
14.1.14.2 Products & services offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.14.3.2 Other developments
14.1.15 NETABOLICS
14.1.15.1 Business overview
14.1.15.2 Products & services offered
14.1.16 CHARNWOOD DISCOVERY
14.1.16.1 Business overview
14.1.16.2 Products & services offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 THE MATHWORKS, INC.
14.1.17.1 Business overview
14.1.17.2 Products & services offered
14.1.17.3 Recent developments
14.1.17.3.1 Product enhancements
14.1.18 ANSYS, INC.
14.1.18.1 Business overview
14.1.18.2 Products & services offered
14.2 START-UP/SME PLAYERS
14.2.1 INSTEM GROUP OF COMPANIES
14.2.2 INSILICO MEDICINE
14.2.3 SCM – SOFTWARE CHEMISTRY & MATERIALS
14.2.4 BIOSYMETRICS, INC.
14.2.5 ATOMWISE INC.
14.2.6 INSITRO
14.2.7 CLINITHINK
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.2 MARKET SIZE ESTIMATION
2.3 DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 BIOSIMULATION MARKET OVERVIEW
4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023)
4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024?2029)
4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP)
5.2.1.4 Need to curtail drug discovery and development costs
5.2.1.5 Growth in biologics and biosimilars markets
5.2.2 RESTRAINTS
5.2.2.1 Lack of standardization
5.2.2.2 Data availability and quality
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging applications
5.2.3.2 Use of biosimulation solutions for pediatric drug development
5.2.4 CHALLENGES
5.2.4.1 Difficulties in matching complexity of biological systems and processes
5.2.4.2 Shortage of biosimulation and modeling experts
5.3 ECOSYSTEM ANALYSIS
5.3.1 SOFTWARE PROVIDERS
5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES
5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
5.3.4 REGULATORY BODIES
5.3.5 ACADEMIC & RESEARCH INSTITUTIONS
5.4 CASE STUDY ANALYSIS
5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING
5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER
5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
5.5 VALUE CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
5.6.1 BARGAINING POWER OF SUPPLIERS
5.6.2 BARGAINING POWER OF BUYERS
5.6.3 THREAT OF SUBSTITUTES
5.6.4 THREAT OF NEW ENTRANTS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY ANALYSIS
5.7.1 REGULATORY LANDSCAPE
5.7.1.1 North America
5.7.1.2 Europe
5.7.1.3 Asia Pacific
5.7.1.4 Latin America
5.7.1.5 Middle East & Africa
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS
5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Mathematical modeling
5.9.1.2 Software platforms
5.9.1.3 Quantitative systems pharmacology (QSP)
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Data analytics
5.9.2.2 Machine learning and AI
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 In silico trials
5.10 INDUSTRY TRENDS
5.10.1 DISCOVERY OF BIOMARKERS
5.10.2 ADOPTION IN PERSONALIZED MEDICINE
5.11 PRICING ANALYSIS
5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE)
5.12 KEY CONFERENCES & EVENTS, 2024–2025
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 BUYING CRITERIA
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.15 END-USER ANALYSIS
5.15.1 UNMET NEEDS
5.15.2 END-USER EXPECTATIONS
5.16 INVESTMENT & FUNDING SCENARIO
5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET
5.17.1 KEY USE CASES
5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.17.2.1 Case study
5.17.2.2 Bioinformatics market
5.17.2.3 Drug discovery services market
5.17.2.4 Drug discovery informatics market
5.17.3 USER READINESS & IMPACT ASSESSMENT
5.17.3.1 User readiness
5.17.3.1.1 Pharmaceutical & biotechnology companies
5.17.3.1.2 Contract research organizations
5.17.3.2 Impact assessment
5.17.3.2.1 User A: Pharmaceutical & biotechnology companies
5.17.3.2.1.1 Implementation
5.17.3.2.1.2 Impact
5.17.3.2.2 User B: Academic & research institutes
5.17.3.2.2.1 Implementation
5.17.3.2.2.2 Impact
6 BIOSIMULATION MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 SOFTWARE
6.2.1 STANDALONE MODULES
6.2.1.1 Molecular modeling & simulation software
6.2.1.1.1 Growing importance of molecular modeling & simulation in drug discovery and development to accelerate market growth
6.2.1.2 PK/PD modeling & simulation software
6.2.1.2.1 Pivotal role in early drug development phase to boost market growth
6.2.1.3 PBPK modeling & simulation software
6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market
6.2.1.4 Toxicity prediction software
6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market
6.2.1.5 Clinical trial simulation software
6.2.1.5.1 High failure rate of clinical trials to accelerate growth
6.2.1.6 Other biosimulation software
6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS
6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms
6.3 SERVICES
6.3.1 CONSULTING & ADVISORY
6.3.1.1 Need to focus on core competencies to drive need for consulting & advisory services
6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT
6.3.2.1 Need for well-trained professionals and experts to accelerate market growth
6.3.3 DATA ANALYSIS & INTERPRETATION
6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services
7 BIOSIMULATION MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DRUG DISCOVERY
7.2.1 TARGET IDENTIFICATION & VALIDATION
7.2.1.1 Need for identification of optimal targets in drug discovery to drive market
7.2.2 LEAD IDENTIFICATION & OPTIMIZATION
7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate market growth
7.3 DRUG DEVELOPMENT
7.3.1 PRECLINICAL TESTING
7.3.1.1 PK/PD
7.3.1.1.1 Critical role of PK/PD studies in drug development to drive market
7.3.1.2 ADME/Toxicology
7.3.1.2.1 Growing role in selection of potent drug molecules to boost market growth
7.3.2 CLINICAL TRIALS
7.3.2.1 Phase I
7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth
7.3.2.2 Phase II
7.3.2.2.1 Efficiency in dose assessment and product efficacy to drive growth
7.3.2.3 Phase III
7.3.2.3.1 Need to curtail large costs involved in trials to propel demand
7.3.2.4 Phase IV/Post-marketing surveillance
7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption
7.4 DISEASE MODELING
7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH
7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
7.5.1 PRODUCTION PLANNING & OPTIMIZATION
7.5.1.1 Need for proper production planning and execution to drive market growth
7.5.2 QUALITY CONTROL & PROCESS MONITORING
7.5.2.1 Adherence to maintaining product quality to fuel market growth
7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT
7.5.3.1 Need to forecast demand effectively to drive market growth
7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING
7.5.4.1 Need to maintain operational continuity to support market growth
7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS
7.6 OTHER APPLICATIONS
8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH
8.3 CARDIOVASCULAR DISEASES
8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET
8.4 NEUROLOGICAL DISORDERS
8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
8.5 INFECTIOUS DISEASES
8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
8.6 OTHER THERAPEUTIC AREAS
9 BIOSIMULATION MARKET, BY REVENUE MODEL
9.1 INTRODUCTION
9.2 LICENSE-BASED MODELS
9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET
9.3 SUBSCRIPTION-BASED MODELS
9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
9.4 SERVICE-BASED MODELS
9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION
9.5 PAY-PER-USE MODELS
9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH
10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL
10.1 INTRODUCTION
10.2 ON-PREMISE MODELS
10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
10.3 CLOUD-BASED MODELS
10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD
10.4 HYBRID MODELS
10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION
11 BIOSIMULATION MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
11.3 CONTRACT RESEARCH ORGANIZATIONS
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
11.4 ACADEMIC & RESEARCH INSTITUTES
11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
11.5 REGULATORY BODIES
11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH
11.6 OTHER END USERS
12 BIOSIMULATION MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
12.2.2 US
12.2.2.1 Rising government funding for pharmaceutical R&D to drive market
12.2.3 CANADA
12.2.3.1 Increasing funding by Canadian government in healthcare to drive market
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
12.3.2 GERMANY
12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation
12.3.3 UK
12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
12.3.4 FRANCE
12.3.4.1 Growing R&D pipeline for clinical trials to drive market
12.3.5 ITALY
12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
12.3.6 SPAIN
12.3.6.1 Established network of research centers to propel market
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market
12.4.3 INDIA
12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation
12.4.4 JAPAN
12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth
12.4.5 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Advancing biosimulation in region to support market growth
12.5.3 MEXICO
12.5.3.1 Government initiatives to enhance digital health to propel market growth
12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12.6.2 GCC COUNTRIES
12.6.2.1 Increase in healthcare investments to support market growth
12.6.3 REST OF MIDDLE EAST & AFRICA
13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET
13.3 REVENUE ANALYSIS, 2019–2023
13.4 MARKET SHARE ANALYSIS, 2023
13.4.1 CERTARA, USA (US)
13.4.2 DASSAULT SYST?MES (FRANCE)
13.4.3 SCHRЦDINGER, INC. (US)
13.4.4 SIMULATIONS PLUS (US)
13.4.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. (CANADA)
13.5 RANKING OF KEY MARKET PLAYERS
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
13.6.1 STARS
13.6.2 EMERGING LEADERS
13.6.3 PERVASIVE PLAYERS
13.6.4 PARTICIPANTS
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
13.6.5.1 Company footprint
13.6.5.2 Offering footprint
13.6.5.3 Application footprint
13.6.5.4 End-user footprint
13.6.5.5 Region footprint
13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023
13.7.1 PROGRESSIVE COMPANIES
13.7.2 RESPONSIVE COMPANIES
13.7.3 DYNAMIC COMPANIES
13.7.4 STARTING BLOCKS
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
13.8 COMPANY EVALUATION & FINANCIAL METRICS
13.9 BRAND/PRODUCT COMPARISON
13.10 COMPETITIVE SCENARIO
13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
13.10.2 DEALS
13.10.3 EXPANSIONS
13.10.4 OTHER DEVELOPMENTS
14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 CERTARA, USA
14.1.1.1 Business overview
14.1.1.2 Products & services offered
14.1.1.3 Recent developments
14.1.1.3.1 Product launches & enhancements
14.1.1.3.2 Deals
14.1.1.4 MnM view
14.1.1.4.1 Right to win
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 DASSAULT SYST?MES
14.1.2.1 Business overview
14.1.2.2 Products & services offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Right to win
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 SCHRЦDINGER, INC.
14.1.3.1 Business overview
14.1.3.2 Products & services offered
14.1.3.3 Recent developments
14.1.3.3.1 Deals
14.1.3.4 MnM view
14.1.3.4.1 Right to win
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 SIMULATIONS PLUS
14.1.4.1 Business overview
14.1.4.2 Products & services offered
14.1.4.3 Recent developments
14.1.4.3.1 Product launches & enhancements
14.1.4.3.2 Deals
14.1.4.3.3 Other developments
14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC.
14.1.5.1 Business overview
14.1.5.2 Products & services offered
14.1.5.3 Recent developments
14.1.5.3.1 Product launches & enhancements
14.1.5.3.2 Deals
14.1.6 CHEMICAL COMPUTING GROUP ULC
14.1.6.1 Business overview
14.1.6.2 Products & services offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 ROSA & CO. LLC
14.1.7.1 Business overview
14.1.7.2 Products & services offered
14.1.8 GENEDATA AG (A DANAHER COMPANY)
14.1.8.1 Business overview
14.1.8.2 Products & services offered
14.1.8.3 Recent developments
14.1.8.3.1 Product launches & enhancements
14.1.8.3.2 Deals
14.1.9 PHYSIOMICS PLC
14.1.9.1 Business overview
14.1.9.2 Products & services offered
14.1.9.3 Recent developments
14.1.9.3.1 Deals
14.1.10 IN SILICO BIOSCIENCES
14.1.10.1 Business overview
14.1.10.2 Products & services offered
14.1.11 ALLUCENT
14.1.11.1 Business overview
14.1.11.2 Products & services offered
14.1.11.3 Recent developments
14.1.11.3.1 Deals
14.1.11.3.2 Expansions
14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES
14.1.12.1 Business overview
14.1.12.2 Products & services offered
14.1.12.3 Recent developments
14.1.12.3.1 Product enhancements
14.1.12.3.2 Deals
14.1.12.3.3 Expansions
14.1.13 CELLWORKS GROUP, INC.
14.1.13.1 Business overview
14.1.13.2 Products & services offered
14.1.13.3 Recent developments
14.1.13.3.1 Expansions
14.1.14 VERISIM LIFE
14.1.14.1 Business overview
14.1.14.2 Products & services offered
14.1.14.3 Recent developments
14.1.14.3.1 Deals
14.1.14.3.2 Other developments
14.1.15 NETABOLICS
14.1.15.1 Business overview
14.1.15.2 Products & services offered
14.1.16 CHARNWOOD DISCOVERY
14.1.16.1 Business overview
14.1.16.2 Products & services offered
14.1.16.3 Recent developments
14.1.16.3.1 Deals
14.1.17 THE MATHWORKS, INC.
14.1.17.1 Business overview
14.1.17.2 Products & services offered
14.1.17.3 Recent developments
14.1.17.3.1 Product enhancements
14.1.18 ANSYS, INC.
14.1.18.1 Business overview
14.1.18.2 Products & services offered
14.2 START-UP/SME PLAYERS
14.2.1 INSTEM GROUP OF COMPANIES
14.2.2 INSILICO MEDICINE
14.2.3 SCM – SOFTWARE CHEMISTRY & MATERIALS
14.2.4 BIOSYMETRICS, INC.
14.2.5 ATOMWISE INC.
14.2.6 INSITRO
14.2.7 CLINITHINK
15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
